Latest News
MilliporeSigma Acquires AmpTec to Grow Life Sciences Business
Friday 15 January 2021

Massachusetts, US-based life sciences company MilliporeSigma has acquired Germany based mRNA contract development and manufacturing organisation AmpTec, to expand mRNA capabilities for vaccines, treatments and diagnostics, the company said.

Financial terms were not disclosed.

The deal strengthens MilliporeSigma's capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases.

The acquisition of AmpTec adds to MilliporeSigma's lipid manufacturing expertise, providing an integrated offering across mRNA value chain.
Date Published: 15/01/2021